Research Article
Comparing Long-Term Outcomes of Entecavir and Tenofovir Disoproxil Fumarate in Liver Transplant Patients
Table 2
Baseline characteristics of recipients and donors after matching.
| | Variable | EVT () | TDF () | SD | value |
| | Recipient age (years) | | | 0.02 | 0.822 | | Recipient gender (, % female) | 55 (13.4%) | 10 (9.7%) | 0.11 | 0.320 | | Recipient BMI (kg/m2) | | | 0.02 | 0.837 | | Recipient HCC (, %) | 197 (47.8%) | 46 (44.7%) | 0.06 | 0.566 | | Hypertension (, %) | 65 (15.8%) | 19 (18.5%) | 0.07 | 0.512 | | Diabetes mellitus (, %) | 66 (16.0%) | 20 (19.4%) | 0.09 | 0.408 | | MELD at transplantation | 15 (10-25) | 14 (9-26) | 0.01 | 0.932 | | Baseline eGFR (mL/min/1.73 m2) | 107 (94-116) | 108 (94-119) | 0.08 | 0.539 | | HBsAg (log10 U/mL) | 2.53 (1.62-3.20) | 2.41 (1.43-3.32) | 0.02 | 0.942 | | HBV DNA detectable | 189 (45.9%) | 49 (47.6%) | 0.03 | 0.757 | | Donor age (years) | | | 0.02 | 0.888 | | Donor gender (, % female) | 65 (15.8%) | 17 (16.5%) | 0.02 | 0.857 | | Donor BMI (kg/m2) | | | 0.01 | 0.923 | | Cold ischemic time (hours) | | | 0.02 | 0.890 | | Duration of surgery (hours) | | | 0.01 | 0.896 | | Blood loss (100 mL) | 10 (6-15) | 10 (6-15) | 0.04 | 0.695 | | ABO incompatibility (, %) | 58 (14.1%) | 16 (15.5%) | 0.04 | 0.706 | | Recipient severe postoperative complications (, %) | 136 (33.0%) | 31 (30.1%) | 0.06 | 0.572 |
|
|
Abbreviations: ENT: entecavir; TDF: tenofovir; HBsAg: hepatitis B surface antigen; MELD: Model for End-stage Liver Disease; BMI: body mass index; HBV: hepatitis B; HCC: hepatocellular carcinoma; SD: Standardized difference; eGFR: estimated glomerular filtration rate.
|
